AbbVie’s Boey wins CHMP backing in Europe
Bottom line
Version 1
Allergan Aesthetics, an AbbVie company, said the European Medicines Agency’s Committee for Medicinal Products for Human Use, or CHMP, has issued a positive opinion recommending approval of Boey (trenibotulinumtoxinE) for the temporary improvement of moderate to severe glabellar lines in adults when those lines have an important psychological impact. AbbVie said the opinion covers the centralized EU procedure across 30 EU and EEA markets, with a European Commission decision expected in the coming months. The company says Boey could become the first botulinum neurotoxin serotype E approved in Europe for this use, with phase 3 data showing onset as early as eight hours and a shorter two- to three-week duration of effect. (news.abbvie.com)
Why it matters: This is a human aesthetics story, not an animal health one, but it still matters to veterinary professionals who track large diversified manufacturers, injectable biologics, and regulatory signals across the broader life sciences market. For AbbVie, Boey would add a fast-acting, short-duration option to its aesthetics portfolio at a time when the company is positioning the product as a differentiated “trial” neurotoxin for patients considering facial injectables. That matters because AbbVie’s broader aesthetics business has been under pressure, and because the same product recently hit a manufacturing-related complete response letter from the FDA in the U.S., underscoring how regional regulatory outcomes can diverge even when clinical data appear supportive. (fiercepharma.com)
What to watch: The next milestone is the European Commission’s final decision, plus any details on launch timing, clinician training, and whether AbbVie resolves the U.S. manufacturing questions without new clinical requirements. (news.abbvie.com)
Key facts
- Brand
- Boey
- Generic name
- trenibotulinumtoxinE
- Company
- Allergan Aesthetics, part of AbbVie
- Regulatory status
- Positive CHMP opinion
- Indication
- Temporary improvement of moderate to severe glabellar lines in adults with an important psychological impact
- Region
- 30 EU and EEA markets
- Key trial data
- Phase 3 onset as early as eight hours; duration about two to three weeks
- Pivotal studies
- M21-500 and M21-508
- Next step
- European Commission decision expected in the coming months
Version 2
Allergan Aesthetics, part of AbbVie, has won a positive opinion from the EMA’s CHMP for Boey, or trenibotulinumtoxinE, to temporarily improve moderate to severe glabellar lines in adults whose condition has an important psychological impact. If the European Commission follows the recommendation, the product would be cleared through the EU centralized procedure for 30 EU and EEA markets, giving AbbVie a potential new entry in facial aesthetics and what it describes as the first botulinum neurotoxin serotype E for this indication in Europe. (news.abbvie.com)
The decision is notable because Boey is being positioned differently from longer-lasting neurotoxins already on the market. AbbVie’s pitch is speed and reversibility: phase 3 studies found effects beginning as early as eight hours after treatment, with efficacy lasting about two to three weeks. That shorter window could appeal to adults who want a quicker-on, quicker-off treatment course, and AbbVie has framed the product as a way for some patients to try facial injectables without committing to the longer duration typically associated with established toxins such as Botox. (news.abbvie.com)
According to AbbVie, the CHMP opinion was supported by two pivotal phase 3 trials, M21-500 and M21-508, which met all primary and secondary endpoints in adults with moderate to severe glabellar lines. The company said treatment-emergent adverse events were similar to placebo, both after a single treatment and through up to three consecutive treatments. Earlier conference materials from IMCAS 2026 also highlighted pooled phase 3 analyses and patient-reported outcomes suggesting high treatment satisfaction, natural-looking results, and improvement in appearance-related psychological impact. (news.abbvie.com)
AbbVie has already started laying the commercial groundwork. In its May 21, 2026 announcement, the company said it plans to begin training healthcare professionals on the appropriate use of Boey and is preparing for launch in the coming months if the Commission grants approval. It also said marketing applications are under review in multiple other countries, suggesting the EU opinion is part of a broader global rollout strategy rather than a one-off regional event. (news.abbvie.com)
Industry context makes the CHMP opinion more consequential. Just weeks earlier, the FDA issued a complete response letter for trenibotulinumtoxinE in the U.S., and AbbVie said the issue was tied to manufacturing information rather than safety, efficacy, or a need for new clinical data. Fierce Pharma reported that AbbVie remains confident it can address the agency’s comments promptly. Taken together, the EU and U.S. developments suggest the product’s clinical package may be broadly intact, while manufacturing execution could determine how quickly AbbVie turns regulatory momentum into revenue. That’s an inference based on AbbVie’s statements and the FDA-related reporting. (fiercepharma.com)
Expert reaction in the public domain was limited at the time of writing, but AbbVie’s own medical affairs and R&D leaders have emphasized the product’s differentiation around rapid onset, short duration, and patient choice. Conference programming at IMCAS 2026 also shows the company has been building a scientific narrative around subgroup analyses, prior toxin exposure, and patient-reported outcomes, which is often how aesthetics companies prepare clinicians and key opinion leaders ahead of launch. (news.abbvie.com)
Why it matters: For veterinary professionals, this is less about companion animal care than about keeping tabs on how major biopharma companies manage innovation, manufacturing risk, and market segmentation across injectable biologics. AbbVie’s handling of Boey shows how companies are trying to create narrower, more customizable treatment profiles, and how a positive scientific opinion in Europe can coexist with a manufacturing setback in the U.S. For readers tracking the business of animal health and adjacent life sciences, it’s a reminder that regulatory nuance, not just trial success, often determines commercial timing. (news.abbvie.com)
What to watch: The immediate next step is the European Commission decision, which EMA materials indicate typically follows a CHMP positive opinion, while AbbVie’s near-term priorities are likely to include clinician education, launch readiness in Europe, and a response to the FDA’s manufacturing questions in the U.S. (news.abbvie.com)